Global Stem Cells Market Set to Reach $32.57 Billion by 2031

SHERIDAN, Wyo., Sept. 7, 2026 /CourierPR/ -- Wissen Research, a global market intelligence and consulting firm, has released a new study forecasting significant growth in the stem cells market over the next five years. According to the report, the global stem cells market is expected to expand from approximately $18.9 billion in 2026 to $32.57 billion by 2031, at a compound annual growth rate (CAGR) of 11.5%.

The growth is driven by several factors. Firstly, the rising interest in regenerative medicine and the increasing use of cell-based therapies are key contributors. Additionally, an aging population and the prevalence of chronic and degenerative diseases are pushing healthcare systems and biotech companies to explore stem cell-based treatment options. These therapies are seen as alternatives or complements to conventional treatments, particularly for conditions such as cancer, neurological disorders, cardiovascular disease, and orthopedic issues.

Improvements in the sourcing, processing, and storage of stem cells are also facilitating the transition from lab research to clinical use. Induced pluripotent stem cells (iPSCs), which can be generated from adult tissue, are receiving particular attention due to their potential to sidestep ethical questions associated with embryonic stem cells. Allogeneic therapies, which are derived from donor cells and can be produced in bulk, are gaining traction for their scalability and off-the-shelf manufacturing potential.

The report highlights that the pharmaceutical and biotechnology sectors are at the forefront of stem cell research and development, with increasing investment in clinical trials and cell therapy pipelines. Better cell acquisition, culture, and cryopreservation techniques are improving the consistency and commercial scalability of these therapies. Beyond therapy, stem cells are also being used in drug discovery, toxicity testing, and disease modeling, providing pharmaceutical companies with faster and more relevant tools for evaluating new compounds.

North America remains the largest market for stem cells, supported by a concentration of major pharmaceutical and biotechnology companies, well-established research institutions, and mature clinical trial infrastructure. However, the Asia-Pacific region is expanding at the fastest pace, driven by rising healthcare investment and expanding biotech infrastructure in countries such as China, Japan, South Korea, and India.

Several strategic developments have recently taken place in the stem cells market. In March 2026, Applied StemCell and Cellipont Bioservices announced a collaboration aimed at accelerating the development of iPSC-derived cell therapies by pairing engineering and banking capabilities with manufacturing and regulatory support. In January 2026, Aspect Biosystems and Novo Nordisk deepened their existing partnership, with Aspect gaining access to Novo Nordisk's islet cell and hypoimmune cell engineering technology, as well as additional funding support. Also in January 2026, South Korea's MEDIPOST raised approximately $140 million to advance its donor-derived mesenchymal stem cell therapy through late-stage clinical trials and expand manufacturing capacity.

The study notes that adult stem cells, particularly hematopoietic and mesenchymal types, continue to dominate the market due to their well-established clinical use in transplantation and tissue regeneration. These cells have a safety profile that makes them the default starting point for many new therapeutic programs. On the therapy side, the shift toward allogeneic, donor-derived approaches reflects an industry-wide push towards standardized, scalable production, which could significantly lower costs and expand patient access over time.

Wissen Research's analysis indicates that the global stem cells market is segmented by product, application, technology, therapy, end-user, and region. The report provides detailed forecasts, competitive insights, and growth opportunities for companies operating in this space. For instance, adult stem cells led the market by product type in 2025, capturing about 72% of global revenue, reflecting their established track record in transplantation and tissue repair applications.

The research underscores that sustained investment in manufacturing scalability, regulatory navigation, and strategic partnerships will be crucial for companies aiming to capture a larger share of this growth. As cell processing technologies mature and regenerative medicine moves into mainstream clinical practice, stem cells are expected to become a central pillar of the broader biotechnology and pharmaceutical landscape.